Novobiocin analogues with second-generation noviose surrogates

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Heat shock protein 90 (Hsp90) is a crucial molecular chaperone and a validated therapeutic target in cancer treatment.
• Novobiocin, the first identified Hsp90 C-terminal inhibitor, served as a lead compound.
• Structure-activity relationship studies identified amine surrogates for the noviose sugar moiety of novobiocin.

Purpose of the Study:

• To synthesize and evaluate novel Hsp90 inhibitors with diverse N'-amino substituents.
• To assess the anti-proliferative efficacy of these analogues against breast cancer cell lines.
• To investigate the mechanism of action, specifically Hsp90 client protein degradation.

Main Methods:

• Synthesis of novel Hsp90 inhibitor analogues.
• In vitro anti-proliferative assays using two human breast cancer cell lines.
• Western blot analysis to confirm Hsp90-dependent client protein degradation.

Main Results:

• Compound 37j exhibited the most significant anti-proliferative activity among the tested analogues.
• Compound 37j induced Hsp90 client protein degradation at mid nanomolar concentrations.
• The observed activity is dependent on Hsp90 inhibition.

Conclusions:

• Novel Hsp90 inhibitors with modified N'-amino substituents show potent anti-cancer activity.
• Compound 37j represents a promising lead candidate for further development in breast cancer therapy.
• Targeting Hsp90 through C-terminal inhibition remains a viable strategy for cancer treatment.